CMAJ • February 12, 2008; 178 (4). doi:10.1503/cmaj.070586.
© 2008 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Résumé
Right arrow Online Appendix
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sheehy, O.
Right arrow Articles by Rinfret, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sheehy, O., MSc
Right arrow Articles by Rinfret, S., MD MSc
Related Collections
Right arrow Other health policy
Right arrow Drugs: cardiovascular system
Right arrow Regulation
Right arrowRelated Articles

Restrictive access to clopidogrel and mortality following coronary stent implantation

Odile Sheehy, MSc, Jacques LeLorier, MD PhD and Stéphane Rinfret, MD MSc

From the Pharmacoeconomics and Pharmacoepidemiology Unit (Sheehy, LeLorier, Rinfret), Centre Hospitalier de l'Université de Montréal Research Centre, and the Division of Cardiology (Rinfret), Department of Medicine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Que.


Figure 118
View larger version (30K):
[in this window]
[in a new window]

  		Figure 1: Selection of the study population. Note: RAMQ = Régie de l'assurance maladie du Québec.

 

View this table:
[in this window]
[in a new window]

  		Table 1.

 

View this table:
[in this window]
[in a new window]

  		Table 2.

 

View this table:
[in this window]
[in a new window]

  		Table 3.

 

Figure 218
View larger version (29K):
[in this window]
[in a new window]

  		Figure 2: Survival curves for patients who underwent percutaneous coronary intervention with stenting between January 2000 and December 2004. Note: CI = confidence interval. *No. at risk excludes patients who became ineligible for drug coverage during the previous period of follow-up.

 

Figure 318
View larger version (22K):
[in this window]
[in a new window]

  		Figure 3: Crude and adjusted risk of death among patients who underwent stent implantation between January 2000 and September 2004. *Adjusted (forward stepwise selection) for sex; age; Régie de l'assurance maladie du Québec drug plan maximum monthly copayment; chronic disease score; length of stay in hospital for stent implantation; no. of days in hospital in the year before stent implantation; no. of visits to emergency room, family physician, cardiologist, other specialists in the year before stent implantation; concomitant acetylsalicylic acid use; compliance to nonrestrictive cardiovascular drugs and year of stent implantation. {dagger}Despite appearing to be nonsignificant, the adjusted hazard ratios for adherence to nonrestricted cardiovascular drug therapy, hospital length of stay, number of other specialist visits and admission to hospital in the year before stent implantation were each significant (95% CI excluding 1).